Studies give new insight into polio eradication

Looking at long-term OPV use and at fractional IPV dosage

The New England Journal of Medicine has published today two studies on polio eradication, offering useful new insights both for the pre- and post-eradication era.

In the first study, Helen Jenkins from Imperial College London et al, examined the implications of the circulating vaccine-derived poliovirus (cVDPV) in Nigeria. The study reaffirms that cVDPVs can regain transmissibility and pathogenicity that is similar to that of wild polioviruses. For the pre-eradication era, this supports the 2007 recommendation of the Advisory Committee on Poliomyelitis Eradication that cVDPVs be responded to in the same manner as wild poliovirus outbreaks. For the post-eradication era, this study reinforces the importance of solid planning for the management of long-term poliovirus risks – especially cVDPVs – in particular the eventual cessation of oral polio vaccine use in routine immunization programmes.

The second study, by Dr Ali Jafer Mohammed from the Ministry of Health in Oman, et al, presents the results of a clinical trial on fractional doses of inactivated polio vaccine (IPV) in Oman. The trial compared seroconversion rates with fractional IPV doses (1/5th of a full dose) to whole dose IPV in infants to evaluate this potential strategy for making the vaccine more affordable for use in low- and low-middle income countries if needed. The data found that in that setting, fractional doses of IPV administered intradermally at 2, 4 and 6 months, as compared with full doses of IPV given intramuscularly in the same schedule, achieve similar seroconversion rates, though with lower antibody titers. Together with our partners, the Global Polio Eradication Initiative is pursuing its work on evaluating a variety of approaches to achieve affordable IPV options for the post-OPV era.

The need to effectively manage cVDPVs both in the pre- and post-eradication eras, and the importance of pursuing strategies to reduce the cost of IPV for the post-eradication era, were underscored in the accompanying editorial ‘The bumpy road to polio eradication’, by Dr John F Modlin.

Related

Related News

   31/03/2023

A word from the Chair: 2023 – Aiming for Success through Ongoing Analysis of Global Effort

Rigorous independent review to assess status to meeting end-2023 critical goals

   30/03/2023

Two years since rollout of novel oral polio vaccine type 2 (nOPV2): How’s it all working out?

An interview with co-leads of GPEI’s nOPV Working Group on nOPV2 field use to date

   21/03/2023

Polio programme provides vital support to nationwide measles vaccination in Afghanistan

21 March 2023

   16/03/2023

GPEI Statement on cVDPV2 detections in Burundi and Democratic Republic of the Congo

16 March 2023

   15/03/2023

Rotary International President insists Rotarians have to finish the job of eradicating polio

Rotary International President, Jennifer Jones, is on a brief tour of London. Speaking at the House of Commons she said that Rotary had to deliver on its promise to the children of the world that it would help to eradicate polio.

   10/03/2023

Eastern Mediterranean health leaders call for redoubled efforts for a defining year for polio

On Tuesday 28 February 2023, ministers and high-level delegates from across the Eastern Mediterranean Region participated in the seventh meeting of the Regional Subcommittee for Polio Eradication and Outbreaks.